||||||||||BGB-24714 / BeiGene Enrollment open, Combination therapy, Monotherapy, Metastases: BGB-24714-101: A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - Jul 7, 2022 P1, N=244, Recruiting, Sponsor: BeiGene In a total of 25 breast cancer cell lines treated with TNF?, BGB-24714 potently inhibited the in vitro proliferation of 5 breast cancer cells with EC50 < 100 nM. Not yet recruiting --> Recruiting